DE602005014380D1 - Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743 - Google Patents

Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743

Info

Publication number
DE602005014380D1
DE602005014380D1 DE602005014380T DE602005014380T DE602005014380D1 DE 602005014380 D1 DE602005014380 D1 DE 602005014380D1 DE 602005014380 T DE602005014380 T DE 602005014380T DE 602005014380 T DE602005014380 T DE 602005014380T DE 602005014380 D1 DE602005014380 D1 DE 602005014380D1
Authority
DE
Germany
Prior art keywords
ecteinescidine
pegylated liposomal
liposomal doxorubicin
doxorubicin combined
combined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005014380T
Other languages
German (de)
English (en)
Inventor
Erard Gilles
Lars-Axel Sternas
Ovid Trifan
De Velde Helgi Van
April Teitelbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Ortho Biotech Products LP
Original Assignee
Pharmamar SA
Ortho Biotech Products LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36096124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005014380(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmamar SA, Ortho Biotech Products LP filed Critical Pharmamar SA
Publication of DE602005014380D1 publication Critical patent/DE602005014380D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602005014380T 2004-10-26 2005-10-26 Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743 Expired - Lifetime DE602005014380D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62216304P 2004-10-26 2004-10-26
PCT/GB2005/050189 WO2006046080A2 (en) 2004-10-26 2005-10-26 Pegylated liposomal doxorubicin in combination with ecteinescidin 743

Publications (1)

Publication Number Publication Date
DE602005014380D1 true DE602005014380D1 (de) 2009-06-18

Family

ID=36096124

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005014380T Expired - Lifetime DE602005014380D1 (de) 2004-10-26 2005-10-26 Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743

Country Status (26)

Country Link
US (1) US20090117176A1 (enExample)
EP (1) EP1827500B1 (enExample)
JP (2) JP4554684B2 (enExample)
KR (1) KR101287918B1 (enExample)
CN (1) CN101119750B (enExample)
AT (1) ATE430586T1 (enExample)
AU (1) AU2005298364B2 (enExample)
BR (1) BRPI0518250A2 (enExample)
CA (1) CA2582452C (enExample)
CY (1) CY1110329T1 (enExample)
DE (1) DE602005014380D1 (enExample)
DK (1) DK1827500T3 (enExample)
ES (1) ES2326825T3 (enExample)
HR (1) HRP20090345T1 (enExample)
IL (1) IL182352A (enExample)
MX (1) MX2007004744A (enExample)
NO (1) NO328958B1 (enExample)
NZ (1) NZ554765A (enExample)
PL (1) PL1827500T3 (enExample)
PT (1) PT1827500E (enExample)
RS (1) RS50822B (enExample)
RU (1) RU2359700C2 (enExample)
SI (1) SI1827500T1 (enExample)
UA (1) UA87877C2 (enExample)
WO (1) WO2006046080A2 (enExample)
ZA (1) ZA200703396B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
SK287901B6 (sk) * 2000-11-06 2012-03-02 Pharma Mar, S. A. Use of Ecteinascidin 743 for preparation of medicament for effective antitumor treatment
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
CA2544320A1 (en) 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
NZ554761A (en) 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
KR101376634B1 (ko) 2006-06-19 2014-03-27 더 존스 홉킨스 유니버시티 리포좀아제에 의한 치료제의 종양­특이적 전달
EP2201141A1 (en) * 2007-10-19 2010-06-30 Pharma Mar S.A. Prognostic molecular markers for et-743 treatment
AU2017335648B2 (en) * 2016-09-27 2022-02-17 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
RU2657835C1 (ru) * 2017-11-28 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ получения системы для доставки противоопухолевого препарата в клетки опухоли

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
PT1067933E (pt) * 1998-04-06 2007-11-15 Univ Illinois Ecteinascidinas semi-sintéticas
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
AU2001281232A1 (en) * 2000-08-11 2002-02-25 City Of Hope The anti-neoplastic agent ET-743 inhibits trans activation by SXR
ES2256305T3 (es) * 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
SK287901B6 (sk) * 2000-11-06 2012-03-02 Pharma Mar, S. A. Use of Ecteinascidin 743 for preparation of medicament for effective antitumor treatment
WO2002076459A1 (en) * 2001-03-06 2002-10-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
US7387790B2 (en) * 2001-06-15 2008-06-17 Cornerstone Pharmaceuticals Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
JP2005509650A (ja) * 2001-10-19 2005-04-14 ファルマ・マール・ソシエダード・アノニマ 癌治療における抗腫瘍化合物の改良した使用
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
WO2004006755A2 (en) * 2002-07-16 2004-01-22 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Support bra for ultrasonic breast scanner
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
CA2544320A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
EP1768671A2 (en) * 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
NZ554761A (en) * 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
DE602006020335D1 (de) * 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
CA2652035A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments

Also Published As

Publication number Publication date
EP1827500A2 (en) 2007-09-05
CY1110329T1 (el) 2015-01-14
JP4554684B2 (ja) 2010-09-29
ES2326825T3 (es) 2009-10-20
ZA200703396B (en) 2008-11-26
HK1107766A1 (en) 2008-04-18
US20090117176A1 (en) 2009-05-07
CN101119750B (zh) 2013-03-06
NZ554765A (en) 2010-01-29
NO328958B1 (no) 2010-06-28
RS50822B (sr) 2010-08-31
DK1827500T3 (da) 2009-08-31
IL182352A (en) 2016-07-31
EP1827500B1 (en) 2009-05-06
WO2006046080A3 (en) 2006-10-19
JP2009292850A (ja) 2009-12-17
KR20070108135A (ko) 2007-11-08
AU2005298364A1 (en) 2006-05-04
RU2359700C2 (ru) 2009-06-27
JP2008517991A (ja) 2008-05-29
BRPI0518250A2 (pt) 2008-11-11
CA2582452C (en) 2010-09-07
RU2007119545A (ru) 2008-12-10
PL1827500T3 (pl) 2009-09-30
KR101287918B1 (ko) 2013-07-19
CN101119750A (zh) 2008-02-06
MX2007004744A (es) 2007-10-23
PT1827500E (pt) 2009-08-05
AU2005298364B2 (en) 2009-03-26
CA2582452A1 (en) 2006-05-04
SI1827500T1 (sl) 2009-10-31
IL182352A0 (en) 2007-07-24
HRP20090345T1 (en) 2009-08-31
ATE430586T1 (de) 2009-05-15
WO2006046080A2 (en) 2006-05-04
WO2006046080A8 (en) 2007-07-12
UA87877C2 (en) 2009-08-25
NO20072543L (no) 2007-07-13

Similar Documents

Publication Publication Date Title
NO20072543L (no) Anti-cancer-behandling
IL273765A (en) Combinations and forms of administration of therapeutic agents and combined treatment
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
AU2001297644A1 (en) B/b-like fragment targeting for the purposes of photodynamic therapy and medical imaging
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
IL155781A0 (en) Effective antitumor treatments
DE602004023183D1 (de) Gegen antikörper gerichtete photodynamische therapie
BR0116972A (pt) Métodos e dispositivos para administração de substâncias na camada intradérmica da pele para absorção sistêmica
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
WO2006069217A3 (en) Small molecule cyclin d1 ablative agents
BRPI0409870A (pt) uso de irinotecano para tratamento de cáncer de mama resistente
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
AUPR227100A0 (en) Composition for use in the treatment of patients with kidney stones
GB0022216D0 (en) Human FAP-a-specific antibodies for use in cancer therapy

Legal Events

Date Code Title Description
8363 Opposition against the patent